EUVIMEDEUVIMED entdecken
Crossref

Integrated DFT, Molecular Docking, and In Silico ADME Analysis of New Benzimidazole Derivatives as Promising Anticancer Candidates Targeting MCF‐7 Cells

Nuaman F Alheety, Ahmed A Al-Kubaisi, Bilal J M Aldahham, Sameer A Awad iD, Noureddine Raouafi, Mustafa A Alheety, Rafaâ Besbes

Chemistry & Biodiversity · 2026-02 · 23 (2)

DOI: 10.1002/cbdv.202503385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 12.02.2026. Verfasst von Nuaman F Alheety und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Department of Chemistry, Analytical Chemistry and Electrochemistry Lab (LR99ES15), University of Tunis El Manar, Tunis El Manar, …. Hauptthemen laut MEDLINE: Benzimidazoles, Molecular Docking Simulation, Antineoplastic Agents, Density Functional Theory. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to synthesize new benzimidazole compounds and assess their anticancer potential in vitro using the human breast cancer cell line Michigan Cancer Foundation 7 (MCF‐7). Using innovative molecular docking and computational analyses, this study investigates the therapeutic potential of newly synthesized benzimidazole derivatives by focusing on a protein that is strongly inhibited by doxorubicin, a widely used cancer treatment. Benzimidazole derivatives were synthesized via multiple approaches and were thoroughly characterized by Fourier transform infrared spectroscopy (FTIR) and 1 H NMR spectroscopy, as well as theoretical analyses. The results showed that Compounds A4 and A5 exhibited good potency against the tested breast cancer cell line, with IC 50 values of 142.6 and 187 µg/mL, respectively. Density functional theory (DFT) calculations were performed at the level to determine the most stable molecular conformation and its electrostatic and electronic properties. Molecular docking studies revealed that the effectiveness of Compounds ( A1–A8 ) is comparable with that of doxorubicin ( B ), an FDA‐approved anticancer molecule against estrogen receptor‐α (ERα) protein, which is responsible for many side effects. The interaction of the A8 compound with protein 1A52 causes the best negative binding energy (−7.85 kcal/mol), whereas the calculated value for the B compound is −8.783 kcal/mol. Compounds ( A1 , A2 , A3 , A4 , A5 , A6 , and A7 ) show a good binding energy for 1A52 (−5.41, −7.14, −6.29, −6.39, −6.65, −7.69, and −6.56 kcal/mol, respectively). Benzimidazole derivatives ( A1–A8 ) may therefore be proposed as new anticancer agents targeting ERα protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesMolecular Docking SimulationAntineoplastic AgentsDensity Functional TheoryHumansMCF-7 CellsDrug Screening Assays, AntitumorCell ProliferationStructure-Activity RelationshipMolecular StructureEstrogen Receptor alphaDose-Response Relationship, Drug

Stichwörter der Autor:innen

benzimidazolesbreast cancerdensity functional theory (DFT) calculationsdoxorubicinestrogen receptor‐α proteinmolecular docking

Substanzen

BenzimidazolesAntineoplastic AgentsEstrogen Receptor alpha

Autor:innen und Institutionen

  • Faculty of Science, Department of Chemistry, Analytical Chemistry and Electrochemistry Lab (LR99ES15), University of Tunis El Manar, Tunis El Manar, Tunisia.
  • Department of General Science, College of Basic Education, University of Anbar, Ramadi, Al Anbar, Iraq.
  • Department of Forensic Evidence, College of Science, University of Al Maarif, Ramadi, Al Anbar, Iraq.
  • Department of Applied Chemistry, College of Applied Sciences, University of Anbar, Ramadi, Iraq.
  • Department of Medical Laboratories Techniques, College of Health and Medical Techniques, University of Al Maarif, Ramadi, Al Anbar, Iraq.
  • Department of Nursing, Al-Hadi University College, Baghdad, Iraq.

ORCID-Profile: Sameer A Awad

Zitieren

APA

Alheety, N. F., Al-Kubaisi, A. A., Aldahham, B. J. M., Awad, S. A., Raouafi, N., Alheety, M. A., & Besbes, R. (2026). Integrated DFT, Molecular Docking, and In Silico ADME Analysis of New Benzimidazole Derivatives as Promising Anticancer Candidates Targeting MCF‐7 Cells. Chemistry & Biodiversity, 23(2). https://doi.org/10.1002/cbdv.202503385

Vancouver

Alheety NF, Al-Kubaisi AA, Aldahham BJM, Awad SA, Raouafi N, Alheety MA, et al. Integrated DFT, Molecular Docking, and In Silico ADME Analysis of New Benzimidazole Derivatives as Promising Anticancer Candidates Targeting MCF‐7 Cells. Chemistry & Biodiversity. 2026;23(2). doi:10.1002/cbdv.202503385

BibTeX
@article{Alheety2026,
  author = {Alheety, Nuaman F and Al-Kubaisi, Ahmed A and Aldahham, Bilal J M and Awad, Sameer A and Raouafi, Noureddine and Alheety, Mustafa A and Besbes, Rafaâ},
  title = {Integrated DFT, Molecular Docking, and In Silico ADME Analysis of New Benzimidazole Derivatives as Promising Anticancer Candidates Targeting MCF‐7 Cells},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  volume = {23},
  number = {2},
  doi = {10.1002/cbdv.202503385}
}
Kostenlos starten →